Efficacy of Adenosine in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

A PRISMA-Compliant Meta-Analysis

Qijun Gao, MD, Bo Yang, MD, Yi Guo, MD, and Feng Zheng, MD

Abstract: Whether adenosine offers cardioprotective effects when used as an adjunctive therapy for patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) remains controversial. To evaluate, via meta-analysis, the efficacy of adenosine in patients with AMI undergoing PCI.

Randomized controlled trials (RCTs) published in Medline, Embase, and the Cochrane Central Register of Controlled Trials.

RCTs of patients with AMI undergoing primary PCI, comparing adenosine treatment and placebo groups and reporting mortality, thrombolysis in myocardial infarction (TIMI) flow grade, myocardial blush grade (MBG), re-infarction, left-ventricular ejection fraction (LVEF), ST-segment elevation resolution (STR), recurrent angina, or heart failure (HF).

Risk of bias was assessed by the Cochrane guidelines and publication bias by Egger’s test. For studies reported in multiple publications, endpoints differed among included RCTs. Performance, publication, and reporting biases remain possible.

Adenosine therapy appears to improve several outcomes in patients with AMI after PCI, but there is no evidence that adenosine can reduce mortality rates.

(Medicine 94(32):e1279)

INTRODUCTION

According to the World Health Organization, more people die from cardiovascular disorders each year than from any other cause worldwide. The Global Burden of Disease study classified ischemic heart disease as the leading cause of global mortality, accounting for 1.4 and 5.7 million deaths in developed and developing regions, respectively.1 Each year, more than 3.0 million people experience acute ST-elevation myocardial infarction (STEMI). The first choice of treatment for STEMI is primary percutaneous coronary intervention (PCI).2 Although PCI is successful in most cases, up to 40% of patients do not achieve complete myocardial reperfusion despite successful treatment of the culprit lesion. This phenomenon is defined as “no-reflow.”3 Acute myocardial infarction (AMI) with no-reflow after primary PCI is difficult to treat and strongly associated with poor in-hospital and long-term outcomes.

In experimental animals, adenosine reduces ischemia/reperfusion injury, limits infarct size, and improves ventricular function.4 However, studies with adenosine in patients with AMI undergoing PCI have yielded controversial results. For example, 2 meta-analyses failed to draw definitive conclusions on clinical outcomes.5,6 Therefore, we performed a meta-analysis to reevaluate the efficacy of adenosine in patients with AMI undergoing PCI.

METHODS

The present meta-analysis was performed in accordance with established methods laid out in the Cochrane guidelines.7

Abbreviations: AE = adverse event, AMI = acute myocardial infarction, CI = confidence interval, HF = heart failure, LVEF = left-ventricular ejection fraction, MACE = major adverse cardiovascular event, MBG = myocardial blush grade, MD = mean difference, PCI = percutaneous coronary intervention, RCT = randomized control trial, RR = risk ratio, STEMI = ST-segment elevation myocardial infarction, STR = ST-segment resolution, TIMI = thrombolysis in myocardial infarction.
and in compliance with the PRISMA\textsuperscript{8} statement for reporting systematic reviews and meta-analyses in healthcare interventions. The study was approved by the Ethics Committee of Renmin Hospital of Wuhan University.

**Literature Search**

Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for randomized controlled trials (RCTs) published between January 1995 and December 2014; no language restrictions were considered. The following search terms were used: adenosine, ST-elevation myocardial infarction, AMI, and/or PCI.

**Study Selection and Inclusion Criteria**

Two reviewers performed study selection independently, with any disagreements resolved through discussion and with the aid of a third reviewer, if necessary. Studies were considered potentially eligible for the meta-analysis if they met the following criteria: CTS involving patients with AMI undergoing primary PCI, comparing an adenosine treatment group with a placebo group, and reporting at least one of the following outcomes: mortality, thrombolysis in myocardial infarction (TIMI) flow grade, myocardial blush grade (MBG), re-infarction, left-ventricular ejection fraction (LVEF), ST-segment elevation resolution (STR), or heart failure (HF). Trials were excluded if they were abstracts, letters, and reviews.

**Data Extraction and Quality Assessment**

Two reviewers independently undertook the data extraction and quality assessment procedures. Disagreements were resolved through discussion, aided by the opinion of a third reviewer if necessary. The following information was extracted from the studies: author, year, design, duration, sample size, study patient population, clinical outcomes, angiographic outcomes, cardiac imaging-related outcomes, and STR. If the report of a study did not contain all of the details required, then an email was sent to the authors to ask for the missing information. For studies reported in multiple publications, data were extracted from the most complete publication, with the other publications serving as supplements. In trials with more than 2 arms, arms using different dosing schedules were merged to avoid duplicating the control arm. Risk of bias was assessed in accordance with guidelines in the Cochrane Handbook. Publication bias was tested by the Egger’s test.

**Statistical Analyses**

For continuous data, mean differences (MDs) and the corresponding 95% confidence intervals (CIs) were analyzed. For dichotomous data, risk ratios (RRs) were analyzed. Study heterogeneity was assessed for each outcome. Homogenous outcomes were analyzed by fixed-effects models. For heterogeneous outcomes, clinical heterogeneity across studies was assessed and, if present, addressed by sensitivity or subgroup analyses. If significant heterogeneity remained, then a random-effects model or descriptive analyses were used, as appropriate. Statistical analyses were performed by using relevant software (RevMan 5.2 or STATA12.0, for Egger’s test). A 2-sided $P$ value $<0.05$ was considered statistically significant.

**RESULTS**

**Literature Search**

Of the 2403 articles identified (Embase/Medline 2188 and CENTRAL 215), 252 articles were potentially relevant. After screening the titles and abstracts of these articles, 218 studies were excluded. The remaining 34 studies were retrieved for a more detailed evaluation. Nineteen studies were excluded because they had no control group (3 studies),\textsuperscript{9–11} had different study populations (12 studies),\textsuperscript{12–23} were duplicate publications of the same study population (3 studies),\textsuperscript{19,24–25} or were not RCTs (1 study).\textsuperscript{26} Thus, 15 clinical trials were included in the final analysis\textsuperscript{7–41} (Figure 1).

**Endpoints**

Table 1 lists the endpoints used in each study.\textsuperscript{27–41} Angiographic outcomes (TIMI flow grade and MBG) were measured at the end of balloon dilatation or after PCI with stenting. The cardiac imaging-related outcome (LVEF) was assessed by echocardiography or magnetic resonance imaging at different time intervals. We tried to pool the data for LVEF and HF assessed 1 month to 1 year after PCI; however, 2 papers that evaluated LVEF and 2 papers that evaluated HF only provided these data at 2 weeks after PCI. Ten studies reported STR, which was defined as the resolution of ST-segment elevation $\geq 70\%$ (8 studies) or $\geq 50\%$ (2 studies).

**Study and Patient Characteristics**

Trials included in this meta-analysis comprised 1736 patients (control group, $n = 858$; adenosine group, $n = 878$). All 15 trials compared between a placebo arm and an adenosine arm. Adenosine was administered by an intravenous (IV) protocol (3 studies) or by an intracoronary (IC) protocol (12 studies), including boluses or continuous infusion. Results of the meta-analyses are shown in Figures 2–12. Baseline characteristics of individual trials are given in Table 1.

**Quality Assessment of Included Trials**

All of the included studies were RCTs. Although they did not describe the method of randomization or allocation concealment, the outcomes were assessed by researchers who were blinded to the results or independent of the study. The overall...
The risk of bias of the included studies was moderate (Figure 13). There was no evidence of publication bias, according to the nonsignificant results of the Egger’s test for TIMI flow grade, HF, LVEF, or STR (Figure 14).

OUTCOMES

Mortality Rates

Among 14 studies reporting data on all-cause mortality for 1686 participants, a fixed-effects model revealed no evidence of a reduction in all-cause mortality with adenosine compared with placebo (RR: 0.73, 95% CI: 0.42–1.28,  \( P = 0.27, I^2 = 0\%\); Figure 2). Seven studies reported data on cardiovascular mortality for 621 participants. There was no evidence of a reduction in cardiovascular mortality with adenosine compared with placebo, according to a fixed-effects model (RR: 0.52, 95% CI: 0.23–1.16,  \( P = 0.11, I^2 = 0\%\); Figure 3).

HF and LVEF

Seven trials reported data on HF at 1 week to 1 year after PCI for 750 participants. According to the results of a fixed-effects model (RR: 1.17, 95% CI: 0.95–1.45,  \( P = 0.12, I^2 = 0\%\); Figure 4), there was no evidence of a reduction in HF with adenosine compared with placebo.

TABLE 1. Summary of Randomized Studies Comparing Adenosine Versus Placebo

| Trial                        | No. of Cases/Controls | Follow-Up, mo | Route | Dose                  | Endpoints                                      | STR % |
|------------------------------|-----------------------|---------------|-------|-----------------------|------------------------------------------------|-------|
| Marzilli et al            | 27/27                 | In hospital   | IC    | 4 mg in 1 min         | HF, mortality, no-reflow, re-infarction         | NA    |
| Stoeel et al               | 27/22                 | 12            | IC    | 60 mg in 5–10 min     | HF, mortality, STR                              | 70    |
| Fokkema et al              | 226/222               | 1             | IC    | 120 µg twice          | AE, mortality, re-infarction, STR, no-reflow    | 70    |
| Desmet et al               | 56/54                 | 4             | IC    | 4 mg bonus            | Mortality, LVEF, no-reflow, STR                 | 70    |
| Grygier et al              | 35/35                 | 12            | IC    | 1 mg RCA, 2 mg        | MACE, LVEF, no-reflow, STR                      | 70    |
| Wang et al                 | 35/34                 | 1             | IV    | 50 µg/kg/min for 3 h  | HF, LVEF, mortality, re-infarction             | NA    |
| Tong et al                 | 130/128               | 12            | IC    | 2 mg in 1 min         | MACE, no-reflow, STR                            | 70    |
| Petronio et al             | 30/30                 | 6             | IC    | 4 mg in 1 min         | Mortality, LVEF, no-reflow, STR                 | 50    |
| Micari et al               | 14/16                 | 1             | IV    | 50–70 µg/kg/min for 3 h | AE, LVEF, mortality                             | NA    |
| Niccoli et al              | 80/80                 | 1             | IC    | 120 µg bolus + 2 mg   | AE, MACE, no-reflow, STR                        | 70    |
| Garcia-Dorado et al        | 100/97                | 6             | IC    | 2.25 mg/min for 2 min | LVEF, mortality, no-reflow                      | 70    |
| Ji et al                    | 23/27                 | 1             | IC    | 300 µg                | AE, LVEF, TIMI                                  | NA    |
| Akturk et al               | 16/15                 | 6             | IC    | 240 µg                | LVEF, mortality, STR, TIMI                      | 50    |
| Zhang et al                | 32/31                 | 1             | IV    | 50–70 µg/kg/min for 3 h | HF, LVEF, mortality, no-reflow, re-infarction | NA    |
| Darahim et al              | 20/40                 | In hospital   | IC    | 6 mg bonus            | LVEF, mortality, no-reflow, re-infarction       | 70    |

AE = adverse event; HF = heart failure; IC = intracoronary; IV = intravenous; LCA = left coronary artery; LVEF = left-ventricular ejection fraction; MACE = major adverse cardiovascular event; NA = not available; RCA = right coronary artery; STR = ST-segment elevation resolution; TIMI = thrombolysis in myocardial infarction.
effects model, there was a significant reduction in the incidence of HF with adenosine compared with placebo (RR: 0.65, 95% CI: 0.43–0.97, \( P = 0.03 \), \( I^2 = 45.1\% \); Figure 4). Ten trials with 678 participants reported data on LVEF at 1 week to 1 year after PCI. Compared with placebo, adenosine did not significantly improve LVEF according to a random-effects model (MD: 2.29, 95% CI: 0.43–0.97, \( P = 0.09 \), \( I^2 = 0\% \)).

No-Reflow and Myocardial Reperfusion

Adenosine should be administered before reperfusion to improve the coronary TIMI flow. One study in which adenosine was administered after PCI was excluded to reduce heterogeneity. Eleven trials with 1556 participants reported data on TIMI flow grade <3. According to the results of a fixed-effects model, compared with placebo, adenosine administered before reperfusion reduced the incidence of TIMI flow grade <3 after PCI (RR: 0.62, 95% CI: 0.45–0.85, \( P = 0.003 \), \( I^2 = 29\% \); Figure 6). Six trials with 1108 participants reported data on MBG after PCI. According to the results of a fixed-effects model, compared with placebo, adenosine reduced the incidence of MBG = 0 to 1 after PCI (RR: 0.81, 95% CI: 0.67–0.98, \( P = 0.03 \), \( I^2 = 36\% \); Figure 7). Ten trials with 1361 participants reported STR. An incidence of STR ≥50% or 70% after PCI was observed more frequently in the adenosine group than in the control group, according to the results of a fixed-effects model (RR: 1.21, 95% CI: 1.10–1.32, \( P < 0.00001 \), \( I^2 = 36\% \); Figure 8).

Re-Infarction

Six studies assessed re-infarction in 1138 participants. According to fixed-effects models, there was no evidence of a reduction in re-infarction (RR: 0.83, 95% CI: 0.38–1.82, \( P = 0.64 \), \( I^2 = 0\% \)) with adenosine at short-term follow-up (Figure 9).

Adverse Events (AEs)

Five RCTs with 648 people reported data on bradycardia, 3 RCTs with 578 people reported data on hypotension, and 8 RCTs with 1232 participants reported data on atrioventricular (AV) block. Compared with placebo, adenosine was not associated with a higher incidence of hypotension (RR: 2.79, 95% CI: 0.76–10.25, \( P = 0.12 \), \( I^2 = 71\% \)), according to a random-effects model (Figure 10). However, there was a greater likelihood of AV block (fixed-effect model—RR: 6.45, 95% CI: 3.77–11.06, \( P < 0.00001 \), \( I^2 = 0\% \); Figure 11) or bradycardia (random-effect model—RR: 3.47, 95% CI: 1.03–11.71, \( P = 0.05 \), \( I^2 = 66\% \); Figure 12) in the adenosine group compared with the placebo group.

![FIGURE 3. Forest plot of adenosine versus placebo for cardiovascular mortality. Overall and individual risk ratios and 95% confidence intervals are reported.](image1)

![FIGURE 4. Forest plot of adenosine versus placebo for heart failure. Overall and individual risk ratios and 95% confidence intervals are reported.](image2)
Subgroup and Sensitivity Analyses

We performed subgroup analyses to assess the effects of IC versus IV adenosine for the outcomes of LVEF and HF, and regular-dose (IC bolus of 0.24–2.25 mg) versus high-dose adenosine (IC bolus of 4–6 mg) for the outcome of LVEF. In all 3 trials that included an IV subgroup, IV adenosine improved the LVEF compared with placebo. IC bolus of regular-dose adenosine was associated with improved LVEF (MD: 2.68, 95% CI: 0.66–4.70, P = 0.01, I^2 = 9%), whereas IC bolus of high-dose adenosine was associated with a worsened LVEF (MD: -2.40; 95% CI: -4.72 to -0.09, P = 0.04, I^2 = 82%; Figure 5) compared with placebo. IC adenosine reduced the occurrence of HF compared with the placebo group, according to a fixed-effects model (RR: 0.54, 95% CI: 0.33–0.88, P = 0.01, I^2 = 0%).

Several sensitivity analyses were conducted to explore the robustness of the results, by removing each study 1 at a time. These analyses did not indicate that any single study influenced the overall results for STR or TIMI flow grade <3.

DISCUSSION

In this meta-analysis of 15 RCTs involving 1736 participants to study the impact of adenosine on patients with AMI undergoing primary PCI, adenosine treatment was not found to have any effect on mortality or re-infarction. However, because of the insufficient sample size, the meta-analysis had limited ability to study these endpoints with adequate power. On the other hand, adenosine appeared to offer potentially beneficial effects on myocardial reperfusion, the occurrence of HF and no-reflow, besides, IV and IC regular-dose adenosine improved LVEF.

Adenosine is an endogenous nucleoside found in large quantities in the myocardial and endothelial cells. It activates 4 receptors, producing physiological effects that attenuate many of the proposed mechanisms of reperfusion injury. Adenosine is a well-known adjunctive therapy for AMI. Experimental models and animal studies have demonstrated that adenosine plays a protective role in reperfusion injury when administered in the perireperfusion period, and that it decreases
FIGURE 7. Forest plot of adenosine versus placebo for myocardial blush grade 0 to 1. Overall and individual risk ratios and 95% confidence intervals are reported.

FIGURE 8. Forest plot of adenosine versus placebo for ST-segment elevation resolution. Overall and individual risk ratios and 95% confidence intervals are reported.

FIGURE 9. Forest plot of adenosine versus placebo for re-infarction. Overall and individual risk ratios and 95% confidence intervals are reported.

FIGURE 10. Forest plot of adenosine versus placebo for bradycardia. Overall and individual risk ratios and 95% confidence intervals are reported.
neutrophil-mediated mechanical obstruction of the capillary channels. Owing to its potent arteriolar vasodilator properties, adenosine can block both the release of vasoconstrictors (e.g., endothelin, leukotrienes, platelet-activating factor) by activated platelets and neutrophils, as well as the effects of vasoconstrictors present in the vascular bed after reperfusion.

Adenosine markedly inhibits superoxide anion production by neutrophils and decreases the number of neutrophils in the reperfused bed. Adenosine, via upregulation of thrombospondin-1, can increase the blood capillary density at the interface between normal and ischemic tissues after AMI. Furthermore, microRNAs participate in cardiovascular disease processes and function as potential therapeutic targets. Adenosine has been demonstrated to regulate the production of RNAs as signaling molecules. Thus, adenosine can reduce infarct size and improve cardiac function via multiple protective roles in reperfusion injury, angiogenesis, and the modulation of small RNA molecules.

Adenosine administration was associated with a lower incidence of TIMI flow grade <3 and MBG of 0 to 1, and with an increased incidence of STR after PCI. These findings indicate that adenosine was associated with better myocardial reperfusion and less incidence of no-reflow, which should theoretically lead to an improved LVEF. However, adenosine did not have accordantly beneficial effects on LVEF. In subgroup analysis, IV adenosine significantly improved LVEF compared with control in all 3 trials. In contrast, LVEF was improved in the regular-dose IC subgroup, but impaired in the high-dose IC subgroup, compared with placebo. These results suggest that the optimal dose for IC administration has yet to be ascertained.

Some reasons for the lack of consistent beneficial effects of IC adenosine in our meta-analysis may be hypothesized. First, the dose of IC adenosine administered by infusion or bolus had a wide range (0.24–60 mg). Second, when using an IC bolus, most studies gave adenosine within 1 min, which may not be sufficient to provide ideal protection. For example, oxygen-derived free radicals, which are major contributors to reperfusion damage, reach peak concentrations in the coronary vessel between 2 and 3 min after the return of oxygenated blood. Finally, adenosine should be delivered immediately before or after reperfusion. However, 2 studies supplied adenosine as an IC bolus after stenting, thereby missing the most important time period to reduce reperfusion damage.

Observed AEs of adenosine included bradycardia, hypotension, dyspnea, chest pain, flushing, AV block, and, rarely, broncho spasm and headache. Adenosine was associated with a higher incidence of AV block and hypotension compared with placebo. However, all AEs disappeared within 2 to 3 min due to the short half-life of adenosine, and no clinical sequelae were observed.
Three previous meta-analyses have assessed the impact of adenosine on patients with AMI undergoing primary PCI. Mukesh et al. analyzed 7 studies involving 1030 participants who were treated with IC adenosine. They assessed mortality, HF, major adverse cardiovascular event (MACE), STR, LVEF, TIMI flow, MBG, and side effects, but were unable to draw definitive conclusions on any of the clinical outcomes. Their meta-analysis included 2 studies that did not meet our inclusion criteria: one was not an RCT and one used a nonplacebo control group. Aung Naing et al. assessed no-reflow after primary PCI in patients with AMI treated with adenosine and verapamil. Their meta-analysis included 10 RCTs involving 947 participants, including 9 RCTs associated with adenosine and 1 with verapamil. These authors also failed to come to a definitive conclusion on any clinical outcome. Recently, Polimeni et al. reported a meta-analysis of conference abstracts, which included 10 RCTs in which patients were treated with IC adenosine. They found that adenosine treatment improved major cardiovascular AE and HF rates in patients with STEMI treated with PCI. Their findings are partly consistent with our conclusions.

LIMITATIONS

Our meta-analysis included studies using different dosages and administration routes of adenosine, baseline profiles, endpoints, and definitions of the endpoints. There may have been a performance bias due to an imbalance of co-interventions across the intervention and control arms. There was also a potential for publication or reporting bias. However, most of the trials had negative results, which should reduce this potential risk. In addition, Egger’s tests for TIMI flow grade, HF, LVEF, and STR did not indicate any evidence of publication bias.

CONCLUSIONS

Adenosine treatment of patients with AMI undergoing primary PCI appears to be associated with a lower incidence of HF and no-reflow, improved myocardial reperfusion, and relatively better LVEF. However, because of the limitations of this study, this statement should be regarded as hypothesis-generating rather than conclusive. Adenosine did not seem to
have any effect on mortality or re-infarction, although these outcomes were limited by the fact that the sample size was insufficient for achieving adequate power. Larger randomized trials are warranted.

REFERENCES

1. Santulli G. Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. JCVIr. 2013;1:1–2.

2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20.

3. Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon: from the experimental laboratory to the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2008;72:950–957.

4. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation. 1989;80:1388–1399.

5. Mukesh S, Tejaskumar S, Kavia K, et al. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Ther Adv Cardiovasc Dis. 2012;6:101–114.

6. Aung Naing K, Li L, Su Q, et al. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev. 2013;6:CD009503.

7. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Available at: www.cochrane.org/resources/handbook/. (accessed 15.11.14).

8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

9. Lim SY, Bae EH, Jeong MH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J. 2004;68:928–932.

10. Hendler A, Aronovich A, Kaluski E, et al. Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIM. J Invasive Cardiol. 2006;18:32–36.

11. Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol. 2007;85:476–482.

12. Assali AR, Sdringola S, Ghanai M, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of “no reflow” phenomenon. Catheter Cardiovasc Interv. 2000;51:27–31.

13. Quintana M, Hjemdahl P, Sollevi A, et al. Left ventricular function and cardiovascular events following adjunct therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the Attenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol. 2003;59:1–9.

14. Kim SJ, Kim W, Woo JS, et al. Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial. Int J Cardiol. 2012;158:88–92.

15. Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women’s Ischemia Syndrome Evaluation) study. J Am Coll Cardiol. 2010;55:2825–2832.

16. Tian F, Chen YD, Liu SZ, et al. Intracoronary adenosine improves myocardial perfusion in late reperfused myocardial infarction. Chin Med J (Engl). 2008;121:195–199.

17. Vijayalakshmi K, Whittaker VJ, Kudanian B, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92:1278–1284.

18. Tsao TP, Cheng SM, Cheng CC, et al. Comparison of intracoronary adenosine and isosorbide dinitrate on no-reflow/slow flow during rotational atherectomy. Acta Cardiol. 2009;64:225–230.

19. Grygier M, Araszkiewicz A, Lesiak M, et al. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol. 2011;107:1131–1135.

20. Sardella G, Lucisano L, Mancone M, et al. Effect of adenosine intracoronary bolus on myonecrosis occurrence in elective PCI (RACE trial). Int J Cardiol. 2012;155:456–459.

21. Sanati HR, Ghanavati R, Zahedehmehr A, et al. Intracoronary adenosine to prevent myonecrosis in patients with stable angina undergoing percutaneous interventions: a double-blinded randomized controlled trial. J Tehran Univ Heart Center. 2013;8:28–34.

22. De Luca G, Iorio S, Venegoni L, et al. Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS trial). Am J Cardiol. 2012;109:202–207.

23. Niccoli G, Falcioli E, Cosentino N, et al. Impact of accuracy of fractional flow reserve to reduction of microvascular resistance after intracoronary adenosine in patients with angina pectoris or non-ST-segment elevation myocardial infarction. Am J Cardiol. 2014;113:1461–1467.

24. Li Y-B, Tong Z-C, Li Q, et al. Evaluation of short- and long-term efficacy of combined intracoronary administration of high-dose adenosine and tirofiban during primary PCI. Exp Clin Cardiol. 2014;7:1769–1780.

25. Niccoli G, Cristina S, Filippo C. Left ventricular remodeling and 1-year clinical follow-up of the REOPEN-AMI trial. J Am Coll Cardiol. 2014;63:1454–1455.

26. Claeyss MJ, Bosmans J, De Ceuninck M, et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004;94:9–13.

27. Ji ZG, Han JM, Liu G, et al. Effect of adenosine on ischemia-reperfusion injury during percutaneous coronary intervention. J Clin Rehabilitative Tissue Eng Res. 2007;11:10399–10403.

28. Garcia-Dorado D, Garcia-De-Llano-B, Otaegui I, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol. 2014;177:935–941.

29. Niccoli G, Rigattieri S, De Vita MR, et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracorony Nitroprusside Versus Adenosine in Acute Myocardial Infarction). JACC Cardiovasc Interv. 2013;6:580–589.

30. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011;32:867–877.
coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv. 2009;2:323–329.

32. Micari A, Belcik TA, Balsec EA, et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol. 2005;96:1410–1415.

33. Akturk IF, Yalcin AA, Biyik I, et al. Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of no-reflow phenomenon in patients with acute myocardial infarction. Minerva Cardioangiol. 2014;62:389–397.

34. Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154–2159.

35. Petronio AS, De Carlo M, Ciabatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J. 2005;150:1015.

36. Stoel MG, Marques KM, de Cock CC, et al. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. Catheter Cardiovasc Interv. 2008;71:283–289.

37. Tong ZC, Li Q, Chen M, et al. Efficacy comparison of combined intracoronary administration of high-dose adenosine and tirofiban versus intracoronary tirofiban during primary percutaneous coronary intervention in patients with acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41:839–844.

38. Grygier M, Araszkiewicz A, Lesiak M, et al. Effect of new method of intracoronary adenosine injection during primary percutaneous coronary intervention on microvascular reperfusion injury—clinical outcome and 1-year follow-up. Cardiology. 2013;124:199–206.

39. Darahim K, Mahdy MM, Ryan MM, et al. Does high-dose intracoronary adenosine improve regional systolic left ventricular function in patients with acute myocardial infarction? Egypt Heart J. 2014;66:289–297.

40. Wang J, Chen YD, Zhi G, et al. Beneficial effect of adenosine on myocardial perfusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction. Clin Exp Pharmacol Physiol. 2012;39:247–252.

41. Zhang H, Tian N-L, Hu Z-Y, et al. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction. Chin Med J. 2012;125:1713–1719.

42. Grygier M, Araszkiewicz A, Lesiak M, et al. Role of adenosine as an adjunct therapy in the prevention and treatment of no-reflow phenomenon in acute myocardial infarction with ST segment elevation: review of the current data. Kardiol Pol. 2013;71:115–120.

43. Enrens I, Bousquenuad M, Lenoir B, et al. Adenosine stimulates angiogenesis by up-regulating production of thrombospondin-1 by macrophages. J Leukoc Biol. 2015;97:9–18.

44. Charan Reddy KV. Regulatory noncoding RNAs in cardiovascular disease: shedding light on “dark matter”. JCVD. 2014;2:360–369.

45. Wronska A, Kurkowska-Jastrzebska I, Santulli G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. Acta Physiol (Oxf). 2015;213:60–83.

46. Ferrari D, Vitiello L, Izdeko M, et al. Purinergic signaling in atherosclerosis. Trends Mol Med. 2015;21:184–192.

47. Forman MB, Stone W, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev. 2006;24:116–147.

48. Polimeni A, De Rosa S, Sorrentino S, et al. Intracoronary adenosine administration reduces MACE and heart failure in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of RCTs. Giornale Italiano di Cardiologia. 2014;15(Suppl 1):e27.